AstraZeneca reports data from ARCTIC study of Imfinzi and tremelimumab in third-line NSCLC April 24, 2018
EMA validates type II variation for Keytruda with pemetrexed and chemotherapy in NSCLC April 24, 2018
FDA advisory committee recommends baricitinib 2 mg, rejects 4-mg dose in rheumatoid arthritis April 24, 2018
AOBiome Therapeutics initiates phase II study of ammonia oxidizing bacteria product candidate April 24, 2018
Astellas seeks Japanese and U.S. approval for gilteritinib in FLT3 mutation-positive AML April 24, 2018
RSS